Pixantrone - CTI BioPharma

Drug Profile

Pixantrone - CTI BioPharma

Alternative Names: BBR-2278; BBR-2778; Pixantrone dimaleate; Pixuvri

Latest Information Update: 17 Jul 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Vermont
  • Developer Cell Therapeutics; CTI BioPharma
  • Class Anthracyclines; Anthraquinones; Antineoplastics; Isoquinolines; Small molecules
  • Mechanism of Action Alkylating agents; Immunosuppressants; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-Hodgkin's lymphoma
  • Phase III Diffuse large B cell lymphoma; Follicular lymphoma
  • Phase I Cancer
  • Discontinued Breast cancer; Myasthenia gravis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 14 Jun 2018 Safety and efficacy data from the phase I/II PREBEN trial in Non-hodgkin's lymphoma presented at the 23rd Congress of the European Haematology Association (EHA-2018)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer(Metastatic disease) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top